JP2015523963A - プテロスチルベンを使用してｕｄｐ−グルクロノシルトランスフェラーゼ活性を誘導する方法 - Google Patents

プテロスチルベンを使用してｕｄｐ−グルクロノシルトランスフェラーゼ活性を誘導する方法 Download PDF

Info

Publication number
JP2015523963A
JP2015523963A JP2015511433A JP2015511433A JP2015523963A JP 2015523963 A JP2015523963 A JP 2015523963A JP 2015511433 A JP2015511433 A JP 2015511433A JP 2015511433 A JP2015511433 A JP 2015511433A JP 2015523963 A JP2015523963 A JP 2015523963A
Authority
JP
Japan
Prior art keywords
pterostilbene
cancer
ugt
effective amount
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015511433A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015523963A5 (OSRAM
Inventor
バルトス，ジェレミー
デリンジャー，ライアン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chromadex Inc
Original Assignee
Chromadex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chromadex Inc filed Critical Chromadex Inc
Publication of JP2015523963A publication Critical patent/JP2015523963A/ja
Publication of JP2015523963A5 publication Critical patent/JP2015523963A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2015511433A 2012-05-08 2012-11-14 プテロスチルベンを使用してｕｄｐ−グルクロノシルトランスフェラーゼ活性を誘導する方法 Pending JP2015523963A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/466,827 US8841350B2 (en) 2011-05-11 2012-05-08 Method for inducing UDP-glucuronosyltransferase activity using pterostilbene
US13/466,827 2012-05-08
PCT/US2012/064993 WO2013169291A2 (en) 2012-05-08 2012-11-14 Method for inducing udp-glucuronosyltransferase activity using pterostilbene

Publications (2)

Publication Number Publication Date
JP2015523963A true JP2015523963A (ja) 2015-08-20
JP2015523963A5 JP2015523963A5 (OSRAM) 2015-10-29

Family

ID=47142275

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015511433A Pending JP2015523963A (ja) 2012-05-08 2012-11-14 プテロスチルベンを使用してｕｄｐ−グルクロノシルトランスフェラーゼ活性を誘導する方法

Country Status (12)

Country Link
US (2) US8841350B2 (OSRAM)
EP (1) EP2846785A4 (OSRAM)
JP (1) JP2015523963A (OSRAM)
KR (1) KR20150027081A (OSRAM)
CN (1) CN104768543A (OSRAM)
AU (1) AU2012379655B2 (OSRAM)
BR (1) BR112014027646A2 (OSRAM)
CA (1) CA2872623A1 (OSRAM)
IN (1) IN2014DN09990A (OSRAM)
MX (1) MX2014013503A (OSRAM)
WO (1) WO2013169291A2 (OSRAM)
ZA (1) ZA201408893B (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160067193A1 (en) * 2014-09-04 2016-03-10 The Regents Of The University Of California Topical pterostilbene compositions for use in treating uv-induced skin damage and hyperplasia
EP3194032B1 (en) * 2014-09-04 2021-06-23 The Regents of the University of California Topical pterostilbene compositions for use in treating loss of barrier function in skin in burn injurys
WO2016200447A1 (en) * 2015-06-10 2016-12-15 Elysium Health, Inc. Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders
US12134956B2 (en) 2022-10-11 2024-11-05 Halliburton Energy Services, Inc. Liner hanger system
US12398624B2 (en) 2023-07-11 2025-08-26 Halliburton Energy Services, Inc. Self-energizing seal for expandable liner hanger

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011051483A1 (en) * 2009-10-30 2011-05-05 Green Molecular, S.L Pterostilbene (pter) for use in the prevention and/or treatment of skin diseases, damages or injures
WO2013051459A1 (ja) * 2011-10-02 2013-04-11 キユーピー 株式会社 ＲＮＡ干渉によるｍＲＮＡ発現の抑制を促進する促進剤およびその用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6623724B2 (en) * 1996-09-18 2003-09-23 Applied Genetics Incorporated Dermatics Dermatological compositions and methods
US6414037B1 (en) * 1998-01-09 2002-07-02 Pharmascience Pharmaceutical formulations of resveratrol and methods of use thereof
DE10161253A1 (de) 2001-12-13 2003-06-26 Dragoco Gerberding Co Ag Verwendung von Dihydropinosylvin und dessen Derivaten als Inhibitoren
FR2869229B1 (fr) 2004-04-26 2006-08-25 Sederma Soc Par Actions Simpli Utilisation d'un inducteur des ugt par voie topique
ES2246165B1 (es) 2004-07-20 2006-12-01 Universitat De Valencia Uso combinado del pteroestilbeno y la quercetina para la fabricacion de medicamentos utiles en el tratamiento del cancer.
US8426369B2 (en) 2006-12-07 2013-04-23 Rutgers, The State University Of New Jersey Prevention and treatment of colon cancer
US8509879B2 (en) 2007-11-06 2013-08-13 The Regents Of The University Of California Apparatus and method for widefield functional imaging (WiFI) using integrated structured illumination and laser speckle imaging
AU2009204181A1 (en) * 2008-01-08 2009-07-16 David Rubin Method and compositions for administering resveratrol and pterostilbene
US20090324740A1 (en) 2008-06-13 2009-12-31 Albritton Iv Ford D Novel nasal spray
US20100240767A1 (en) 2009-03-23 2010-09-23 Muhammed Majeed Melanogenesis inhibitiuon by 3,5-dimethoxy-4'-hydroxystilbenes and cosmeceutical compositions thereof
US9737495B2 (en) 2009-06-22 2017-08-22 Indus Biotech Private Limited Process for obtaining purified pterostilbene and methods of use thereof
US20110136751A1 (en) 2009-10-06 2011-06-09 Green Molecular Use of Polyphenols in the Treatment of Cancer
US8399712B2 (en) * 2010-02-03 2013-03-19 Laurus Labs Private Limited Pterostilbene cocrystals
US8883218B2 (en) * 2010-03-26 2014-11-11 The Board Of Trustees Of The University Of Arkansas Anti-cancer nanoparticle compositions and methods of use
CN110015962B (zh) 2011-01-28 2022-03-15 肯塔基大学研究基金会 茋类似物和治疗癌症的方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011051483A1 (en) * 2009-10-30 2011-05-05 Green Molecular, S.L Pterostilbene (pter) for use in the prevention and/or treatment of skin diseases, damages or injures
WO2013051459A1 (ja) * 2011-10-02 2013-04-11 キユーピー 株式会社 ＲＮＡ干渉によるｍＲＮＡ発現の抑制を促進する促進剤およびその用途

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CICHOCKI, MICHAL ET AL.: "Pterostilbene is equally potent as resveratrol in inhibiting 12-O-tetradecanoylphorbol-13-acetate ac", MOLECULAR NUTRITION & FOOD RESEARCH, vol. 52, JPN6014040641, 2008, pages 62 - 70, ISSN: 0003344705 *
FEDDI, FATIMA ET AL.: "Abstract 4239: Pterostilbene, a natural polyphenol, elicits full protection against ultraviolet B ra", CANCER RESEARCH, JPN7016001678, 15 April 2011 (2011-04-15), ISSN: 0003344703 *
PAN, MIN-HSIUNG ET AL.: "Pterostilbene Suppressed Lipopolysaccharide-Induced Up-Expression of iNOS and COX-2 in Murine Macrop", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, vol. 56, no. 16, JPN6016023691, 2008, pages 7502 - 7509, ISSN: 0003344704 *
STIVALA, LUCIA A. ET AL.: "Specific Structural Determinants Are Responsible for the Antioxidant Activity and the Cell Cycle Eff", HE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 25, JPN7016001679, 2001, pages 22586 - 22594, ISSN: 0003344706 *

Also Published As

Publication number Publication date
EP2846785A4 (en) 2016-06-15
US20150011650A1 (en) 2015-01-08
WO2013169291A3 (en) 2015-06-18
AU2012379655A1 (en) 2014-11-20
KR20150027081A (ko) 2015-03-11
IN2014DN09990A (OSRAM) 2015-08-14
MX2014013503A (es) 2015-11-13
US20120289605A1 (en) 2012-11-15
WO2013169291A2 (en) 2013-11-14
AU2012379655B2 (en) 2018-01-18
CN104768543A (zh) 2015-07-08
US10039725B2 (en) 2018-08-07
ZA201408893B (en) 2016-08-31
US8841350B2 (en) 2014-09-23
EP2846785A2 (en) 2015-03-18
CA2872623A1 (en) 2013-11-14
BR112014027646A2 (pt) 2017-06-27

Similar Documents

Publication Publication Date Title
Li et al. Protective effects of sulforaphane on diabetic retinopathy: activation of the Nrf2 pathway and inhibition of NLRP3 inflammasome formation
Elshaer et al. Resveratrol: An overview of its anti-cancer mechanisms
Menikdiwela et al. Autophagy in metabolic syndrome: breaking the wheel by targeting the renin–angiotensin system
Bowden Prevention of non-melanoma skin cancer by targeting ultraviolet-B-light signalling
Moldogazieva et al. Oxidative stress and advanced lipoxidation and glycation end products (ALEs and AGEs) in aging and age‐related diseases
Kısmet et al. Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention
Tang et al. Metformin inhibited Nod-like receptor protein 3 inflammasomes activation and suppressed diabetes-accelerated atherosclerosis in apoE−/− mice
Hu et al. Sodium butyrate mitigates type 2 diabetes by inhibiting PERK-CHOP pathway of endoplasmic reticulum stress
Roghani et al. Chronic epigallocatechin-gallate improves aortic reactivity of diabetic rats: underlying mechanisms
Guéant et al. Nutritional models of foetal programming and nutrigenomic and epigenomic dysregulations of fatty acid metabolism in the liver and heart
Mihanfar et al. SIRT1: A promising therapeutic target in type 2 diabetes mellitus
US10039725B2 (en) Method for treating non-melanoma skin cancer by inducing UDP-glucuronosyltransferase activity using pterostilbene
Chen et al. Selenoprotein P is elevated in individuals with obesity, but is not independently associated with insulin resistance
Hussain et al. Systemic down-regulation of delta-9 desaturase promotes muscle oxidative metabolism and accelerates muscle function recovery following nerve injury
La Favor et al. Exercise prevents Western diet-associated erectile dysfunction and coronary artery endothelial dysfunction: response to acute apocynin and sepiapterin treatment
Clayton et al. Promoting healthy cardiovascular aging: emerging topics
Chevillard et al. Nrf3-deficient mice are not protected against acute lung and adipose tissue damages induced by butylated hydroxytoluene
Loh et al. PKC-δ-dependent mitochondrial ROS attenuation is involved as 9-OAHSA combats lipoapotosis in rat hepatocytes induced by palmitic acid and in Syrian hamsters induced by high-fat high-cholesterol high-fructose diet
CA2959756C (en) Topical pterostilbene compositions for use in treating uv-induced loss of barrier function in skin
Lu et al. Oral delivery of the P2Y12 receptor antagonist ticagrelor prevents loss of photoreceptors in an ABCA4−/− mouse model of retinal degeneration
Menozzi et al. Intestinal effects of nonselective and selective cyclooxygenase inhibitors in the rat
Guo et al. Fucoxanthin attenuates angiogenesis by blocking the VEGFR2-mediated signaling pathway through binding the vascular endothelial growth factor
Teng et al. Formoterol, a clinically approved drug, inhibits ferroptosis by suppressing lipid peroxidation and attenuates APAP-induced acute liver injury
So et al. Novel investigational drugs for basal cell carcinoma
CN114377138A (zh) 使用脂氧素、消退素及其类似物稳定动脉粥状硬化斑块的方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150904

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150904

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160628

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160826

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170628

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20171017